Zumutor Receives FDA Response on Pre-Investigational New Drug (PIND) Application for its Novel NK cell Therapeutics ZM008 Against Locally Advanced or Metastatic Solid Tumors - FDA provides very specific recommendation for the proposed ZM008 program - Company intends to submit an IND application for ZM008 this year against locally advanced or metastatic solid tumours [...]
Abrogation of natural killer cell check point pathway LLT1/CD161 by novel anti LLT1 antibody ZM008 and its therapeutic applications in solid cancers.
Maloy Ghosh, Sanghamitra Bhattacharjee, Anurag Tiwari, Ashvini Kumar Dubey, Yogendra Manjunath, Pallavi Lahiri, Amir Horowitz; Zumutor Biologics, Bangalore, India; Precision Immunology Institute/Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY Background: LLT1/CD161 interaction plays important roles in cancer immune surveillance, fine tuning of NK cells responsiveness and down regulating effector [...]
Zumutor Biologics Announces Receipt of a Grant from The United States – India Science & Technology Endowment Board
We are pleased to announce that we have received a grant from the USISTEF to advance our program for the development of monoclonal antibody therapeutics for the treatment of COVID-19. This is a collaborative project in partnership with Prof. Shiladitya Sengupta (Brigham and Women’s Hospital, Cambridge, MA). The novel coronavirus pandemic has created an unprecedented [...]
Major strategies for mining human antibody repertoires are: a) non-combinatorial and b) combinatorial strategies. Non-combinatorial strategies retrieve human Monoclonal Antibodies (mAbs) from single B-cells with the original heavy and light chain pairs while combinatorial strategies involve human antibody library with randomly combined heavy and light chains. Both approaches have led to food and drug [...]
- By Aniket Bangroo, Kirthana MV Sindhe and Subhra Prakash Chakrabarty - Cancer is a formidable disease that may arise when some cells of our body behave in an anomalous fashion giving rise to tumors marked by abnormal growth, cell survivability and the ability to escape immune surveillance. The immune system of our body, [...]
Catalent, the leading global provider of advanced delivery technologies, development, and manufacturing solutions for drugs, biologics, cell and gene therapies, and consumer health products, today announced that it has signed an agreement with Zumutor Biologics, Inc., to manufacture Zumutor’s lead candidate, ZM008, for the treatment of solid tumors. Zumutor is a biologics company that [...]
Zumutor Biologics, an Immuno-Oncology company developing novel mABs to drive transformational changes in the treatment of cancer raises 4Mil$ in series A2 funding taking its total raise to 20Mil$. The round includes funding by new investor Bharat Innovation Fund (BIF) with participation from its existing investor, Accel Partners. Zumutor’s growth strategy is focused on [...]
Kavitha Iyer Rodrigues, CEO, receives the “Women Transforming India 2018” award at Delhi on December 16, 2018 from the Vice President of India. This was organized by NITI Aayog in partnership with the United Nations.
Dr. Maloy Ghosh, Chief Scientific Officer at Zumutor Biologics Inc spoke on “ Human Antibody Library Development for therapeutic monoclonal antibody products” at INNO 2018
Dr. Maloy Ghosh, Chief Scientific Officer at Zumutor Biologics Inc spoke on “ Human Antibody Library Development for therapeutic monoclonal antibody products” at INNO 2018, a two-day Antibody Symposium held on Monday, 3rd December 2018, in Bengaluru, India. The symposium was designed to expand the understanding of scientific advancements in antibody conjugates. Participants included global [...]
Zumutor Biologics Awarded the BioExcellence Emerging Company Award in 2018 by the Karnataka State Government
Receiving the award at the Bangalore Technology Summit, on Friday, November 30,2018, Dr. Sunit Maity , Director-Product Development at Zumutor said “We have raised additional funds this year from our lead investor for ongoing development of our lead immuno oncotherapy molecule to enable IND filing in 2019”.